James Woodward

---

Jim Woodward is a Sector Specialist in the Healthcare practice at Daybreak Capital Partners. Mr. Woodward is an independent consultant in early stage business development, interim management, M&A advisory, and finance, specializing in medical devices, health care services, and diagnostics.

Mr. Woodward has spent over 40 years in life sciences, primarily in early-stage, emerging growth medical device, diagnostic, and healthcare service companies. His operating experience includes CEO, COO, and CFO roles, both full time and interim. He has also served as a strategy consultant with a leading international consulting firm (McKinsey & Company) and as a Partner of a firm focused on life science and medical device commercialization strategy (Technology Commercialization Group, "TCG Medtech").

Mr. Woodward has played a central role in multiple venture capital financings totaling over $100 million, including Advanced Cardiovascular Systems ($7.5 million), Cardiometrics ($15 million), Intelliwire ($3 million), Aprex ($4 million), Ventana Medical Systems ($20 million), Accordant Health Services ($28 million), and Encelle ($29 million).

Among other accomplishments, Mr. Woodward was the lead detail negotiator as CFO of Advanced Cardiovascular Systems in its acquisition by Eli Lilly & Company, and advised Alex Brown & Sons and Eli Lilly in Lilly's acquisition of Hybritech. He advised Interventional Technologies in its sale to Boston Scientific and in a proposed earn-out acquisition by B. Braun, and advised Aprex Corporation in its acquisition by Apria. He negotiated the earn-out sale of Encelle Inc. to Pioneer Surgical Technology, including the back-license of wound care and anti-scarring applications to the Encelle Shareholders' Committee, as well as a co-development and license agreement with Smith & Nephew for Encelle's wound care technology, with an option for Smith & Nephew to acquire.

As a Partner of TCG (www.tcgmedtech.com), Mr. Woodward served numerous offshore clients in their efforts to enter or expand their presence in the US, including Lohmann & Rauscher (Germany/Austria), Mölnlycke (Sweden), Biotec Beta Glucans and Otivio AS (Norway), Medi Productions (France), Eykona Technologies (UK), Otsuka and Nitta Gelatin (Japan), and Global Kinetics Corporation (Australia). Domestic clients included FMC and Avadim Technologies.

Immediately prior to joining TCG, Mr. Woodward was President and CEO of Encelle Inc., a venture-backed developer of tissue-regenerative biopolymers, which was acquired by Pioneer Surgical Technology. Concurrent with his early consulting work with Encelle, he was interim CFO and Director of Accordant Health Services, a disease management company that was acquired by CVS/Caremark.

While still in California, Mr. Woodward served as President and CEO of Cardiometrics during its early product development and commercialization phase, during which he was co-inventor of the FloWire, the only doppler guide wire that provides direct measurement of intracoronary flow. After its public offering, Cardiometrics went through a series of acquisitions and was ultimately acquired by Philips N.V. He also served as Start-up General Manager and Director of Intelliwire, Inc. and as Interim Chairman and CEO of Aprex.

Earlier in his career, Mr. Woodward was CFO and Director of Advanced Cardiovascular Systems, Inc. (acquired by Eli Lilly, now Abbott Vascular), the first medical device company to achieve $100 million in annual sales in less than 5 years from first product launch. After leaving ACS, he played a key management role in the start-up phase of Interventional Technologies (acquired by Boston Scientific) and Ventana Medical Systems (acquired by Roche), serving as co-founder and director of each.

From 1975 to 1981, Mr. Woodward was a consultant with McKinsey & Company, serving in its Dallas/Houston, Amsterdam, Sydney, and San Francisco offices. His engagements included 20-year capital planning and funding models for the state transportation departments of Texas and California, and strategy, organization, and operational improvement studies for clients in the energy, utilities, shipping, manufacturing, food distribution, and restaurant industries, including portfolio reviews that resulted in divestitures. He also managed a multinational team of consultants from six McKinsey offices on a worldwide search for subsea product opportunities for Dutch industry.

Mr. Woodward served as an Officer in the U.S. Navy on the fast attack nuclear submarine USS Tautog (SSN 639). He was awarded a Navy Unit Commendation, Meritorious Unit Commendation, Naval Expeditionary Medal, Vietnam Service Medal, and CINCPACFLT Letter of Commendation.

Mr. Woodward holds an A.B. in Economics from Princeton University and an M.B.A. from Stanford University, Graduate School of Business.